Impact of extracum of curcuma longa in a composition of rectal suppositoria on of lipid peroxidal oxidation indications in the thick intestiness in experimental Crohn’s disease
https://doi.org/10.31146/1682-8658-ecg-175-3-80-86
Abstract
The aim. To conduct a comparative analysis of the effect of turmeric extract and 5-aminosalicylic acid (5-ASA) in the composition of rectal suppositories in clinical symptoms and the content of lipid peroxidation products in the mucous membrane of the large intestine in experimental Crohn’s disease (CD).
Materials and methods. The experiment was performed on 70 non-linear white Wistar rats. CD was modeled by rectal administration of trinitrobenzenesulfonic acid, rectal suppositories were used each 12 hours: with 5-ASA in a dose of 50 mg, with 10% turmeric extract of original composition, weighing 0.3 g each. On the 3rd, 5th and 7th day of CD, the clinical status was determined by the modified Disease activity index scale and the content of lipid peroxidation products in the large intestine mucosa.
Results. In the dynamics of CD in the colon, the content of primary, secondary and final lipid peroxidative products in the heptane and isopropanol phases increases; the severity of clinical signs (weight loss, diarrhea, blood in the fecal masses) increases with increasing content of POL. The use of rectal suppositories with turmeric extract in case of CD reduces the severity of clinical symptoms, reduces the content of lipid peroxidation products mainly in the isopropanol phase of the colon lipid extract; an association was established between the index of clinical activity of CD and the content of lipid peroxidation products in the large intestine. The effectiveness of local application of turmeric extract in the composition of rectal suppositories is comparison with the effectiveness of the use of rectal suppositories with 5-ASA in terms of the clinical activity index and the content of lipid peroxidation products in the large intestine.
About the Authors
M. V. Osikov
South Ural State Medical University, Ministry of health of the Russian Federation
Russian Federation
Russian Federation
Mikhail V. Osikov, Head of the Department of Pathophysiology, professor, Doctor of Medical Sciences
Vorovskogo St., 64, Chelyabinsk, Chelyabinsk area, 454092
E. V. Simonyan
South Ural State Medical University, Ministry of health of the Russian Federation
Russian Federation
Russian Federation
Elena V. Simonyan, Head of the Department of Pharmacy and Chemistry, Pharmaceutical Faculty, Ph.D.
Vorovskogo St., 64, Chelyabinsk, Chelyabinsk area, 454092
A. E. Bakeeva
South Ural State Medical University, Ministry of health of the Russian Federation
Russian Federation
Russian Federation
Alina E. Bakeeva, Laboratory assisstant of the Department of Pharmacy and Chemistry, Pharmaceutical Faculty
Vorovskogo St., 64, Chelyabinsk, Chelyabinsk area, 454092
References
1. Sales-Campos H., Basso P. J., Alves V. B.F. et. al. Classical and recent advances in the treatment of inflammatory bowel diseases. Braz J Med and Biol Res. 2014, no. 48(2), pp. 96–107.
2. Curkovic I., Egbring M., Kullak-Ublick G. Risks of Inflammatory Bowel Disease Treatment with Glucocorticosteroids and Aminosalicylates. Dig Dis, 2013, no.3, pp. 368–373
3. Klinicheskie rekomendatsii rossiskoi gastroenterologicheskoi assotsiatsii I assotsiatsii koloproktologov Rossii po diagno. [Clinical recommendations of Russian gastroenterological association and association of coloproctologists for diagnostics and treatment of Crohn’s disease]. Available at: http://www.gastro.ru/userfiles/R_Krona_2017.pdf (accessed 29 September 2019)
4. Tian T., Wang Z., Zhang J. Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies. Oxid med cell longev. Vol. 2017, Article ID: 4535194
5. Paizullaeva Z., Aleksandrov V. Neiroendokrinnye izmeneniya pri vospalitel’nyh zabolevaniyah i rake tolstoy kishki [Neuroendocrine changes in imflammatory disease and thick colon cancer]. Klinicheskaya meditsina – Clinical medicine, 2010, no. 4. pp. 56–60.
6. Novak E. A., Mollen K. P. Mitochondrial dysfunction in inflammatory bowel disease. Front Cell Dev Biol, 2015. № 3. – P. 62.
7. Te Velde A. A., Pronk I., de Kort F. et al. Glutathione peroxidase 2 and aquaporin 8 as new markers for colonic inflammation in experimental colitis and inflammatory bowel diseases: an important role for H2O2? Eur J Gastroent Hepat. 2008, no. 20(6), pp. 555–560.
8. Schrader M., Fahimi H. D. Peroxisomes and oxidative stress. BBA. 2006, Vol. 1763(12), pp. 1755–1766.
9. Beltran B., Nos P., Dasi F., et al. Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naive and treated Crohn’s disease. Inflamm. Bowel Dis. 2010, no. 16(1), pp. 76–86.
10. Hiller F., Besselt K., Deubel S. et. al. GPx2 induction is mediated through STAT transcription factors during acute colitis. Inflamm. Bowel Dis. 2015, no. 21(9), pp. 2078–2089.
11. Iborra M., Moret I., Rausell F., et al. Role of oxidative stress and antioxidant enzymes in Crohn’s disease. Biochem. Soc. Trans. 2011, no. 39(4), pp. 1102–1106.
12. Prabhu V., Guruvayoorappan C. Protective effect of marine mangrove Rhizophora apiculata on acetic acid induced experimental colitis by regulating anti-oxidant enzymes, inflammatory mediators and nuclear factor-kappa B subunits. Int Immunopharmacol. 2014, no. 18(1), pp. 124–134.
13. Socca E. A., Luiz-Ferreira A., de Faria F. M., et al. Inhibition of tumor necrosis factor-alpha and cyclooxigenase-2 by Isatin: a molecular mechanism of protection against TNBS-induced colitis in rats. Chem.-Biol. Interact. 2014, Vol. 209, pp. 48–55.
14. Ioannidis O., Varnalidis I., Paraskevas G. et. al. Nutritional modulation of the inflammatory bowel response. Digestion. 2011, Vol. 84(2), pp. 89–101.
15. Senhaji N., Kojok K., Darif Y. et. al. The contribution of CD40/CD40L axis in inflammatory bowel disease: an update. Front Immunol, 2015. No. 6, pp. 529.
16. Wallace K., Zheng L., Kanazawa Y. et. al. Immunopathology of inflammatory bowel disease. World J Gastroenterol, 2014, no. 20(1), pp. 6–21.
17. Muthupalani S., Ge Z., Feng Y., et al. Systemic macrophage depletion inhibits Helicobacter bilis-induced proinflammatory cytokine-mediated typhlocolitis and impairs bacterial colonization dynamics in a BALB/c Rag2–/– mouse model of inflammatory bowel disease. Infect Immun. 2012, Vol. 80(12), pp. 4388–4397.
18. Gajdarova A., Koroshchenko G., Aizman R. Influence of turmeric and crcumin on carbohydrate metabolism in alloxan-induced diabetic rats. Modern problems of science and education. 2014, no.5, pp. 597.
19. Gupta S. C., Patchva S., Aggarwal B. B. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J, 2013, no. 15(1), pp.195–218.
20. Morris G. P., Beck P. L., Herridge M. S. et. al. Hapteninduced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989, Vol. 3, pp. 795–803.
21. Cooper, H.S., Murthy, S.N., Shah, R.S. et. al. Clinicopathologicstudy of dextran sulfate sodium experimental murine colitis. Lab. Invest, 1993, no. 69(2), pp. 238–249.
22. Volchegorskyi I. A., Dolgushin I. I. et al. Experimentalnoe modelirovanie i laboratornaya otsenka adaptivnyh reaktsyi organizma [Experimental modelling and laboratory estimating of adaptive reactions of organism]. Chelyabinsk, ChelGPU, 2000. 167 p.
23. Guo, Y. L., Li, X. Z., & Kuang, C. T. Antioxidant Pathways and Chemical Mechanism of Curcumin. Adv Mat Res. 2011, Vol. 236–238, pp. 2311–2314.
24. Anthwal A., Thakur B. K., Rawat M. S. et. al. Synthesis, characterization and in vitro anticancer activity of C-5 curcumin analogues with potential to inhibit TNF-alpha-induced NF-kappaB activation. BioMed Research International Volume 2014, Article ID524161, 10 pages URL: http://dx.doi.org/10.1155/2014/524161
25. Gupta S. C., Tyagi A. K., Deshmukh-Taskar P. et. al. Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. Arch Biochem Biophys. 2014, Vol. 559, pp. 91–99.
Review
For citations:
Osikov M.V., Simonyan E.V., Bakeeva A.E. Impact of extracum of curcuma longa in a composition of rectal suppositoria on of lipid peroxidal oxidation indications in the thick intestiness in experimental Crohn’s disease. Experimental and Clinical Gastroenterology. 2020;(3):80-86. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-175-3-80-86
Views:
452
Email this article 